The Conversation (0)
Nu-Med Plus announced it received a patent approval for their Nitric Oxide delivery technology.
Nu-Med Plus (OTCBB:NUMD) announced it received a patent approval for their Nitric Oxide delivery technology.
As quoted in the press release:
Concentrating on large progressive markets where there is clearly a defined need by the medical community, Nu-Med Plus has developed a Hospital Nitric Oxide (NO) Delivery System that may well reduce the existing high cost of Nitric Oxide treatment presently in use in hospitals. On June 16, 2017 Nu-Med’s patent attorney received notification of the approval of our patent to protect this innovative advancement. “The Nu-Med Plus mission is to expand its intellectual property portfolio and safeguard its low cost NO technology which will add value to the company and increases our competitive advantage,” commented Mr. Jeff Robins, President and CEO of Nu-Med Plus.
Click here to read the full press release.
Source: www.marketwired.com
